Table of Contents

1. A decade of malaria phenotypic screenings: Key lessons on the discovery and development of new antimalarial drugs Esther Fernández, María Isabel Castellote, María Jesús Chaparro, Beatriz Díaz, Jorge Fernández, Mariola Gordo, Laura de las Heras, María Luisa León, Lourdes Rueda and Félix Calderón 2. Medicinal chemistry progression of antimalarial hits from phenotypic whole cell screening of SoftFocus libraries Peter M. Cheuka, Godfrey Mayoka, John Okombo and Kelly Chibale 3. The hybrid antimalarial approach Princy Gupta, Lovepreet Singh and Kamaljit Singh 4. Dealing with schistosomiasis: Current drug discovery strategies Sandra Gemma, Stefano Federico, Simone Brogi, Margherita Brindisi, Stefania Butini and Giuseppe Campiani 5. Shortcuts to schistosomiasis drug discovery: The state-of-the-art José T. Moreira-Filho, Rafael F. Dantas, Mário R. Senger, Arthur C. Silva, Dulcinea M. B. Campos, Eugene Muratov, Floriano P. Silva-Junior, Carolina H. Andrade and Bruno J. Neves 6. Multicomponent reactions: A mighty journey partner for infectious tropical disease drug discovery Diego Muñoz-Torrero, Rodolfo Lavilla, F. Javier Pérez-Areales and Ouldouz Ghashghaei

About the Author

Kelly Chibale is a full Professor of Organic Chemistry at the University of Cape Town (UCT) where he holds the Neville Isdell Chair in African-centric Drug Discovery and Development. He is also a Full Member of the UCT Institute of Infectious Disease & Molecular Medicine, a Tier 1 South Africa Research Chair in Drug Discovery, founding Director of the South African Medical Research Council (SAMRC) Drug Discovery and Development Research Unit at UCT and the Founder and Director of the UCT Drug Discovery and Development Centre (H3D).
Kelly obtained his PhD in Synthetic Organic Chemistry from the University of Cambridge in the UK (1989-1992). This was followed by postdoctoral stints at the University of Liverpool in the UK (1992-94) and at the Scripps Research Institute in the USA (1994-96). He was a Sandler Sabbatical Fellow at the University of California San Francisco (2002), a US Fulbright Senior Research Scholar at the University of Pennsylvania School of Medicine (2008) and a Visiting Professor at Pfizer in the UK (2008).